Afluzole is indicated in- Vaginal Candidiasis Oropharyngeal Candidiasis Esophageal Candidiasis Tinea corporis/Tinea cruris/Tinea pedis/Other Tinea Kerion Pityriasis versicolor Onychomycosis Invasive candidal infections and cryptococcal infections (including meningitis) ... Read more Afluzole is indicated in- Vaginal Candidiasis Oropharyngeal Candidiasis Esophageal Candidiasis Tinea corporis/Tinea cruris/Tinea pedis/Other Tinea Kerion Pityriasis versicolor Onychomycosis Invasive candidal infections and cryptococcal infections (including meningitis) Prevention of cryptococcal meningitis Prevention of fungal infections in immunocompromised patients Systemic Candidiasis and Cryptococcal infection In Superficial Candidiasis In Systemic Candidiasis & Cryptococcal infection Other indications- Fungal urinary tract infections Disseminated candidiasis Prophylaxis for fungal infection in neutropenic cancer patients. Acute treatment of other systemic fungal infections such as coccidioidomycosis and histoplasmosis.
Fluconazole is a triazole antifungal agent. It is a potent inhibitor of fungal cytochrome P-450 dependent enzymes. Cytochrome P-450 enzyme system is essential component of fungal cell membrane which is responsible for the synthesis of ergosterol.
Adults: Vaginal Candidiasis : 150 mg as a single dose. Oropharyngeal Candidiasis : 200 mg in 1st day followed by 100 mg daily for 14 days. Oesophageal Candidiasis : 200 mg in 1st day followed by 100 mg daily for 14-30 days. Tinea corporis/Tinea cruris/Tinea pedis/Other Tinea : 150 mg weekly for 4-6 weeks. Kerion : 50 mg daily for 20 days. Pityriasis versicolor : 400 mg as a single dose. Onychomycosis : 150 mg weekly for 12 months. Invasive candidal infections and cryptococcal infections (including meningitis) : Orally or by IV infusion, 400 mg on first day then 200-400 mg daily. Prevention of cryptococcal meningitis : Orally or by IV infusion 200 mg daily. Prevention of fungal infections in immunocompromised patients : Orally or by IV infusion, 50-400 mg daily. Child over 1 year- In Superficial Candidiasis : 1-2 mg/kg daily. In Systemic Candidiasis & Cryptococcal infection :3-6 mg/kg daily. In serious life threatening infections upto 12 mg/kg daily has been given to children aged 5-13 years (Maximum 400 mg daily) 1 year: 9 kg : 1/2 measuring spoonful 1-2 years: 12 kg : 1 measuring spoonful 2-3 years: 14 kg : 1½ measuring spoonful 3-4 years: 16 kg : 2 measuring spoonful 4-6 years: 20 kg : 2½ measuring spoonful Use in Specific Population- Elderly patient : The normal dose should be used if there is no evidence of renal impairment. Renal Impairment : No adjustment in single dose therapy is required. In multiple dose therapy of patients with renal impairment, normal doses should be given on days 1 and 2 of treatment and there after the dosage intervals should be modified as follows: Creatinine clearance (>41 ml/min): Dosage interval (hours) 24 Creatinine clearance (21-40 ml/min): Dosage interval (hours) 48 Creatinine clearance (10-20 ml/min): Dosage interval (hours) 72 Patients receiving regular dialysis: One dose after every dialysis session Children : Renal clearance in children may be proportionately more rapid than in adults and doses up to 12 mg/kg is recommended.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Afluzole is generally well tolerated. The commonest side-efects associated Afluzole are symptoms associated with the gastrointestinal tract; these include nausea, abdominal discomfort, diarrhoea and fatulence. Other adverse events such as rash are rarely encountered (Incidence less than 1%). In rare cases, as with other azoles, anaphylaxis has been reported.
Fluconazole should not be used in patients with known hypersensitivity to Fluconazole or to related triazole compounds.
In an interaction study, fuconazole increased the prothombin time after warfarin administration in healthy males. Though the magnitude of change was small (12%) careful monitoring of prothombin time in patients receiving coumarin type anticoagulants is recommended. Afluzole has been shown to prolong the serum half-life of concomitantly administed oral sulphonyl ureas (chlorpropamide, gilbenclamide, glipizide and tolbutamide) in healthy volunteers. Afluzole and oral sulphonylureas may be co-administered to diabetic patients, but the possibility of a hypoglycemic episode should be borne in mind. In a kinetic interaction study, co-administration of multiple-dose hydrochlorothiazide to healthy volunteers receiving fuconazole increased plasma concentrations of fuconazole by 40%. An efect of this magnitude should not necessitate a change in the fuconazole dose regimen in subjects recieving concomitant diureties, although the prescribers should bear it in mind. Concomitant administration of fuconazole and phenytoin may increase the level of phenytoin to a clinically signifcant degree. Administration of fuconazole and rifampicin has resulted in a 25% decrease in the AUC and 20% shorter half-life of fuconazole. Patients recieving concomitant rifampicin, an increase in the fuconazole dose should be considered. Two kinetic studies with combined oral contraceptive have been performed using muitiple dose of fuconazole. There were no relevant efects on either hormone level in the 50 mg fuconazole study, while at 200 mg daily the AUCs of ethinyl estradiol and levonorgestrel were increased 40% and 4% respectively. Thus multipule dose use of fuconazole at these dose is unlikely to have an efect on the efcacy of the combined oral contraceptives. Afluzole 50 mg daily does not afect endogenous steroid levels in females. 200-400 mg daily has no clinically singnifcant efect on endogenous steroid levels or on ACTH stimulated response in healthy male volunteers. A kinetic study in renal transplant patients found fuconazole 200 mg daily to slowly increase cyclosporin concentrations. However, in another multiple dose study with 100 mg daily, fuconazole did not afect cyclosporin levels in patients with bone marrow transplants. Cyclosporin plasma concentration monitoring in patients receiving fuconazole is recommended. Interaction studies have shown that when oral fuconazole is co-administered with food. cemetidine, antacids or following total body irradiation for bone marrow transplantation, no clinically signifcant impairment of fuconazole absorption occurs. In placebo-controlled interaction study, the administration of fuconazole 200mg for 14 days resulted in an 18% decrease, in the mean plasma clearance of theophyline, Patients who are receiving dose of theophyline or who are otherwise at increased risk for theophyline toxicity should be observed for sign of toxicity while receiving fuconazole, and the therapy modifed appropriately if sign of toxicity while receiving fuconazole, and the therapy modifed appropriately if sign of toxicity develop. Physicians should be aware that drug-drug interaction studies with other medications have not been conducted, but that such interactions may occur.
in some patients, particularly those with serious underlying diseases such as AIDS and cancer, abnormalities of hepatic, renal, haematological and other biochemical function tests have been observed during treatment with fuconazole, but the clinical signifcance and relationship to treatment is uncertain. Very rarely. patients who died with severe underlying disease and who had received multiple dose fuconazole, had post-mortem fndings which included hapatic necrosis. These patients were receiving multiple concomitant medications, some known to be potentially hepatotoxic, and/or had underlying diseases, which could have caused the hepatic necrosis. Consequently, because a causal relationship with fuconazole cannot be excluded, the risk-beneft ratio of continued fuconazole treatment should be assessed in those patients in whom a signifcant rise of liver enzymes occurs. Patients have rarely developed exfoliative cutaneous reactions, such pa Stevens Johnson Syndrome and toxic epidermal necrolysis, during treatment with fuconazole. AIDS patients are more prone to the development of severe cutaneous reactions to many drugs. If a rash develops in a patients treated for a superfaclal fungal infection which is considered attributable to fuconazole further therapy with this agent should be discontinued. In patients with invasive/ systemic fungal infections who develop rashes, they should be monitored closely and fuconazole should be discontinued if bolbous lesions or erythema multiform develop. Use during lactation: Afluzole is found in human breast milk at concentrations similar to plasma. hence its use in nursing mothers is not recommended. Driving/Use of machinery: Experience with fuconazole indicates that therapy a unlikely to impair a patient's ability to drive or use machinery.